Saturday 17 October 2026
Export MHUAF’s income statement to Excel — free account
Meihua International Medical Technologies Co., Ltd.
MHUAF Healthcare Medical Instruments & Supplies
Meihua International Medical Technologies Co., Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $61.8 million, down 36.2% from fiscal 2024.
6.50
0.00
0.00%
Follow MHUAF
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 2 | 4 | 5 | 4 |
Altman Z-Score |
— | — | — | — | 7.05 | 3.21 | 2.52 | 2.00 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 13.44 | 10.26 | 10.30 | 12.41 | 12.61 | 12.57 | 17.18 |
Beneish M-Score |
— | — | (1.18) | (1.41) | (2.19) | (1.81) | (2.45) | (1.79) |
P/Operating CF |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.72 | (0.69) | (0.86) |
EV/FCF |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | (0.79) | (0.88) |
Quick Ratio |
— | 3.80 | 3.08 | 3.25 | 4.87 | 4.64 | 4.85 | 7.37 |
Current Ratio |
— | 3.88 | 3.17 | 3.34 | 5.60 | 5.27 | 5.26 | 8.42 |
Net Debt/EBITDA |
— | (0.68) | (0.17) | (0.11) | (1.75) | (0.63) | (0.63) | (0.70) |
Debt/Assets |
0.00% | 3.53% | 3.03% | 3.78% | 4.17% | 4.26% | 4.27% | 4.34% |
Debt/Equity |
— | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
Asset Turnover |
— | 2.18 | 0.99 | 0.86 | 0.69 | 0.58 | 0.54 | 0.31 |
Operating CF/Net income |
— | 0.60 | 0.28 | 0.00 | (1.47) | 0.20 | 1.35 | 0.08 |
Capex/Depreciation |
— | 0.00 | (30.75) | (1.34) | (4.75) | (9.21) | (0.23) | (0.03) |
Interest Coverage |
— | 264.50 | 171.04 | 145.33 | 55.48 | 58.51 | 9.50 | 34.30 |
| — | 21.37% | 26.38% | 21.77% | 5.07% | 8.14% | 7.09% | 3.90% | |
| — | 42.16% | 21.25% | 17.25% | 4.16% | 6.93% | 6.06% | 3.45% | |
ROIC |
— | 0.00% | 18.16% | 15.66% | 5.68% | 6.68% | 5.98% | 2.83% |
Return on Tangible Assets |
— | 36.37% | 35.69% | 27.69% | 5.21% | 10.02% | 8.74% | 4.74% |
Average Days of Receivables |
— | 162.33 | 239.98 | 303.41 | 321.51 | 373.95 | 433.13 | 705.08 |
Research and Development Expense of Revenue |
— | 4.03% | 2.80% | 2.62% | 2.87% | 2.84% | 3.57% | 3.86% |
Selling, General and Administrative Expense of Revenue |
— | 11.71% | 12.58% | 10.40% | 18.94% | 14.25% | 14.88% | 12.03% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
— | 3.30 | 445.31 | 520.19 | 441.46 | 405.59 | 354.07 | 164.34 |
Operating CF per Share |
— | 0.39 | 26.63 | (0.27) | (39.14) | 9.51 | 53.48 | 1.52 |
Capex per Share |
— | 0.00 | (80.47) | (4.17) | (11.43) | (18.12) | (0.49) | (0.04) |
Free Cash Flow per Share |
— | 0.39 | (53.84) | (4.44) | (50.57) | (8.62) | 52.99 | 1.47 |
Cash per Share |
— | 0.66 | 35.94 | 40.75 | 114.21 | 70.71 | 63.17 | 40.30 |
Shareholders Equity per Share |
— | 2.47 | 423.68 | 538.84 | 592.39 | 613.36 | 580.84 | 502.48 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 2.47 | 423.68 | 538.84 | 592.39 | 613.36 | 580.84 | 502.48 |
Free Cash Flow |
— | 9.31 | (10.77) | (0.89) | (11.84) | (2.06) | 14.50 | 0.55 |
Working Capital |
— | 39.03 | 46.25 | 68.19 | 111.15 | 107.16 | 116.17 | 135.33 |
Capital Expenditures |
— | (8.95) | (16.09) | (0.83) | (2.68) | (4.34) | (0.13) | (0.02) |
Net Current Asset Value |
— | 39.03 | 46.25 | 68.19 | 110.42 | 107.16 | 116.17 | 135.33 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.18 | 0.01 | 0.03 | 0.04 | 0.00 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.15 | 0.07 | 0.08 | 0.06 | 0.05 | 0.07 | 0.07 |
Cash ROIC |
— | 11.89% | (11.32%) | (0.73%) | (6.87%) | (1.21%) | 7.87% | 0.26% |
Accounts Receivable Turnover |
— | 1.69 | 1.90 | 1.43 | 1.16 | 1.02 | 0.90 | 0.53 |
Accounts Payable Turnover |
— | 3.82 | 4.15 | 3.51 | 3.52 | 4.00 | 4.06 | 3.57 |
Inventory Turnover |
— | 40.58 | 44.15 | 49.84 | 54.98 | 46.66 | 42.03 | 27.38 |
Average Days of Payables |
— | 71.62 | 109.98 | 119.22 | 90.04 | 90.38 | 88.80 | 72.09 |
Days of Inventory on Hand |
— | 7.84 | 9.33 | 7.11 | 6.28 | 9.24 | 8.09 | 14.59 |
Average Receivables |
— | 46.98 | 46.98 | 72.52 | 88.76 | 95.26 | 107.24 | 117.18 |
Average Payables |
— | 12.50 | 12.50 | 18.31 | 18.54 | 15.96 | 15.65 | 11.95 |
Average Inventory |
— | 1.18 | 1.18 | 1.29 | 1.19 | 1.37 | 1.51 | 1.56 |
Average Assets |
— | 36.60 | 89.63 | 121.45 | 150.22 | 167.75 | 179.08 | 196.71 |
Average Common Equity |
— | 72.20 | 72.20 | 96.25 | 123.22 | 142.76 | 152.91 | 173.95 |
Columns are period end dates